TORONTO, ON / ACCESSWIRE / October 16, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ('Intellipharmaceutics' or the 'Company'), a pharmaceutical company specializing in the research
TORONTO, ON / ACCESSWIRE / October 16, 2023 / Intellipharmaceutics International Inc. , a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2023. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Expenditures for R&D were $748,216 for the three months ended August 31, 2023 in comparison to $621,591 the three months ended August 31, 2022. The increase in the R&D expenses during the three months ended August 31, 2023 are attributed to the increase in on going R&D expenses. As of August 31, 2023, our cash balance was $400,102. We currently expect to meet our short-term cash requirements from potential revenues for approved generic products or other collaborations, other available financing and by cost savings resulting from reduced R&D activities and staffing levels.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals.
España Últimas Noticias, España Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
HUGO BOSS Neutral (Goldman Sachs Group Inc.) 13.10.2023 | AnalyseHUGO BOSS Neutral (Goldman Sachs Group Inc.) 13.10.2023 | Analyse | finanzen.net
Leer más »
XFRA ISIN CHANGEEinstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS6025661017 MIND Technology Inc. 16.10.2023 US6025663096 MIND Technology Inc. 17.10.2023 Tausch 10:1KYG508751065 JE
Leer más »